To investigate the metabolic pathogenesis in subjects with subjective tinnitus (ST) having kidney deficiency pattern (KDP) (ST/KDP) in terms of Traditional Chinese Medicine.
INTRODUCTION
Subjective tinnitus (ST) is the perception of sound in the ear or head that does not arise from the external stimulus but originates from within the body. 1 Up to 10% of the population of industrialized countries suffer from chronic ST. 1 Persistent ST usually leads to irritability, fatigue, depression, anxiety, sleep disturbances and concentration difficulties, as well as seriously affects normal daily activities. 2, 3 ST usually results from ear problems, hearing loss, neurologic and psychiatric disorders. Growing studies indicated metabolic disorders were also closely associated with ST. [4] [5] [6] According to the explanation of Traditional Chinese Medicine (TCM), most of ST were attributed to kidney deficiency that represents a unique pathological state. [7] [8] [9] Kidney deficiency pattern (KDP) is a series of external manifestations of kidney deficiency characterized by specific symptoms, such as tinnitus, pain, weakness of the back and knees, low libido, lassitude, hypnosis, dizzy spells, and lethargy. 10, 11 ST accompanied by KDP (ST/KDP) is a common type of disease in clinic. Exploring the pathogenesis of ST/KDP from the perspective of metabolic disorders is one of ways to better understand this hearing impairment and improve its adequate screening and diagnosis. Nevertheless, so far the metabolic pathogenesis of ST/KDP has not been clarified yet. With the rapid development of analytical technology and bioinformatics tools, metabolomics and biomolecular network analysis have become promising approaches for understanding and elucidating the etiology and mechanisms of human diseases and, therefore, utilized extensively in life sciences. 12, 13 Metabolomics has been applied successfully to identify potential biomarkers of diseases in a holistic context. 14, 15 In addition, it has been widely used to explore the mechanisms underlying TCM symptom patterns. [16] [17] [18] The network-based bioinformatics approach is good at analyzing the correlation of the biomarkers and revealing the pathogenesis of diseases. 19 Increasing studies have shown the effectiveness and utility of the network-based systems biology approach for revealing the biological basis of TCM symptom patterns. [20] [21] [22] In the present study, ultra-performance liquid chromatography (UPLC) coupled with quadruple-timeof-flight mass spectrometry (Q-TOF-MS) was applied to characterize ST/KDP metabolic pro fi les. Then the bioinformatics approach was employed to predict biomarkers for identification of ST/KDP, and lastly the metabolomics data from the patients who were disease-free initially and who developed ST/KDP one year later were collected to further verify the predicted results. Thus, the metabolic pathogenesis in ST/KDP subjects was revealed.
MATERIALS AND METHODS

Study population
Enrolled subjects in this study were from 8401 individuals who underwent health screening every year at the community of Beijing city in china. Diagnosis of ST was based on "Tinnitus Diagnosis and Treatment Guidelines" issued by Chinese Medical Association in 2009 as follows: primary complaint of continuous, chronic ST for at least six months; score on the Tinnitus Questionnaire of 40 or more; functionally normal hearing sensitivity by audiometric thresholds with less than 30 dB hearing loss at and below 2000 Hz and less than 40 dB hearing loss at 4000 Hz. Diagnosis of KDP was according to the teaching material "Otolaryngology of Traditional Chinese Medicine" published by China Traditional Chinese Medicine Press and certified by China's 12th Five-Year Plan in 2012 as follows: tinnitus like cicadas, decreased sexual function, soreness and weakness of waist and knees, fatigue, forgetfulness, insomnia, vision loss, pale tongue, deep and fine pulse, etc. After diagnosis of ST, every candidate subject was diagnosed by three senior TCM experts, each with over forty years of experience of TCM teaching, research, and independent practice. KDP confirmed by at least two experts was the final diagnosis of every KDP subject. Exclusion criteria was as follows: age over 75 years or below 18 years; diagnosis of pulsatile tinnitus or objective tinnitus; predisposing disease with tinnitus symptoms amenable to medical or surgical intervention; clinical treatment for tinnitus within previous six months; complications, such as cardiovascular or cerebrovascular diseases, chronic liver disease, gastrointestinal disease, nephropathy, or metabolic syndrome; intake of certain drugs (aspirin, quinine, or salicylate). Consequently, 122 eligible subjects comprised the cohort for this study, including 50 healthy subjects (control group), 50 ST/KDP subjects (ST/KDP group), and 22 healthy → ST/KDP subjects (group of initially healthy subjects who subsequently developed ST/ KDP) ( Figure 1 ). The baseline characteristics of the enrolled subjects, including sex, age and results of their blood biochemical tests, had no significant differences between the groups (Table 1) . This study was approved by the Ethics Committee at the Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences and was conducted according to the standards of the Declaration of Helsinki.
Blood sampling and biochemical testing
Fasting blood samples from health screening population were drawn via venipuncture by clinical nurses. After standing for 2 h at 4 ℃ , the blood samples were centrifuged at 3500 × g for 15 min. The obtained serum was divided into two parts. One part was used for blood biochemical examinations. The remaining serum was for UPLC-Q-TOF-MS analysis.
UPLC-Q-TOF-MS analysis
UPLC-Q-TOF-MS analysis was performed using an Agilent-1200 LC system coupled with an electrospray ionization source (Agilent Technologies, Palo Alto, CA, USA) and an Agilent-6520 Q-TOF mass spectrometer. Separation of all samples was performed on an Eclipse Metabolic biomarkers for subjective tinnitus with KDS Figure 1 Clinical trial design flow diagram Table 1 Baseline characteristics of the enrolled subjects from different groups plus C18 column (1.8 µm, 3.6 mm×100 mm, Agilent) with a column temperature set at 45 ℃. The flow rate was 0.3 mL/min, and the mobile phase consisted of ultrapure water with 0.1% formic acid and acetonitrile. The following gradient program was used: 2% acetonitrile for 0-1.5 min, 2-100% acetonitrile for 1.5-13 min, a wash with 100% acetonitrile for 13-16 min, and a re-equilibration step for 5 min. The sample injection volume was 2 µL. Mass detection was undertaken in the positive ion mode with the following settings: drying gas (N2) flow rate, 8 L/min; gas temperature, 330 ℃; pressure of the nebulizing gas, 35 psig; Vcap, 4000 V; fragmentor voltage, 160 V; skimmer voltage, 65 V; and scan range, m/ z 50-1200. All of the analyses were acquired using the instrument mass spray to ensure accuracy and reproducibility.
Data processing and statistical analysis
The LC-MS raw data were exported by the Agilent Mass Hunter Qualitative Analysis Software (Agilent Technologies, Palo Alto, CA, USA). The data of each sample were normalized to the total area to correct for the MS response shift between injections due to any possible intra-and inter-day variations. Partial least squares discriminant analysis was used for the metabolic profile analysis. Multivariate analysis was performed using SIMCA-P software (Umetrics AB, Umeå, Sweden), version 11. The SAS statistical package (order no. 195557), version 9.1.3, was used for the statistical analysis. Continuous variables were analyzed by the one-way analysis of variance, and the data were expressed as the mean ± standard deviation. Count Variables were analyzed using the χ 2 test. Differences were considered statistically significant if P < 0.05.
IPA analysis
The analyses of the networks and canonical pathways for the metabolites were conducted by using the Ingenuity Pathway Analysis (IPA, http://www.ingenuity. com) to gain insight into the typical metabolic alterations associated with the biomarkers and mechanisms relevant to ST/KDP.
Prediction of the indicative ability of metabolites
Human enzyme-metabolite interaction data were downloaded from the HMDB (http://www.hmdb.ca/) database. Human protein-protein interaction data were collected from the HPRD (http://www.hprd.org/) and Bio GRID (http://thebiogrid.org/) databases. It has been hypothesized that changes in metabolites represented changes in the enzymes that catalyzed formation of these metabolites. Because the changes in enzymes resulted from deregulated upstream pathways in diseases, the metabolites could be used to indicate the abnormal internal molecular state of the body affected by disease. Representative value (RV) was defined as the power of the metabolite to be reliably associated with the abnormality caused by disease. RV depended on the fold change in the metabolite concentration, the number of enzymes that catalyzed metabolite formation, and the importance of every enzyme, which collectively determined the indicative ability of the metabolite to report disease. RV was calculated as follows: where was the representative value of the metabolite m; was the network power of the enzyme that participated in the catalytic formation of the metabolite m; was the number of enzymes participating in the catalytic formation of the metabolite m; was the fold change value of the concentration of metabolite m in disease relative to its concentration in healthy state; and was the total number of deregulated metabolites in disease.
RESULTS
Identification of the metabolites in ST/KDP
Typical base peak chromatograms (BPCs) of serum samples were obtained from the control and ST groups. The multiple pattern recognition methods of the partial least squares discriminant analysis (PLS-DA) was applied to the classification of the metabolic phenotypes and the identification of the differential metabolites. Score plots showed obvious separation between the control and ST/KDP groups ( Figure 2 ). Twelve metabolites in the ST/KDP subjects were different from those of the healthy control subjects. Glutamate was the most representative metabolite for indicating the presence of ST/KDP and corresponding RVs of other metabolites, from serotonin to 8-oxoguanine, lower sequentially ( Table 2) .
Verification of the identified metabolites by using data from the Healthy → ST/KDP subjects Based on a follow-up data set from the Healthy → ST/ KDP subjects, the predicted metabolites responsible for the progression from the healthy stage to ST/ KDP were verified. PLS-DA score plots show ed obvious separation between data obtained at the initial (Table 3) .
Through the comparison of these metabolites with the predicted metabolites, we found that upregulated glutamate, serotonin, orotic acid, and 8-oxoguanine, as well as downregulated taurine, were their common metabolites. The correlation among the metabolites was analyzed using IPA. As shown in Figure 4 , these metabolites mapped onto five canonical pathways: calcium signaling, γ-aminobutyric acid (GABA) receptor signaling, purine and pyrimidine biosynthesis, taurine biosynthesis, and serotonin receptor signaling.
DISCUSSION
ST is the perception of sound for which there is no apparent external cause. Increasing studies have indicated that ST is associated with metabolic disorders and it results from kidney deficiency according to TCM. [7] [8] [9] Knowledge of metabolic pathogenesis of ST/KDP is necessary for a better understanding of this hearing impairment. Therefore, based on ST/KDP subjects from a large population sample, applying UPLC-Q- TOF-MS and bionetwork analysis, we discovered metabolic biomarkers and corresponding pathogenesis associated with ST/KDP. To the best of our knowledge, this study was the first attempt to use metabolic profiles and bionetwork analysis to characterize ST/KDP. Neurotransmitter amino acids such as glutamate, GA-BA and serotonin, as well as amino acids closely related to neurotransmitter metabolism and/or functions, e.g., glutamine and taurine, play a critical role in neurotransmission. Inner ear damage that leads to hearing disorders could impact the levels and distribution of these amino acids in the cochlear nucleus. 23 There was growing evidence that the imbalance of these amino acids, e.g., increased excitatory transmission and/or decreased inhibitory transmission, could disrupt auditory processing and thereby cause tinnitus. 24 Glutamate is the most abundant excitatory neurotransmitter in the vertebrate nervous system. Action potentials trigger release of glutamate from presynaptic neurons. In the opposing postsynaptic neuron, glutamate receptors, such as the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor or the N-methyl-D-aspartic acid (NMDA) receptor, bound glutamate and be activated. 25 It has been demonstrated that the lateral vestibular nucleus projected to the dorsal cochlear nucleus (DCN), and the corresponding glutamatergic synapses relied on the activation of AMPA and NMDA receptors. 26 The vestibular and peripheral auditory systems were closely related anatomically and physiologically, which might have important implications for disorders such as tinnitus. 27 In addition, because of glutamate's role in synaptic plasticity, glutamate was involved in cognitive functions in the brain, so glutamate levels, which could be altered by cochlear damage, likely affected generation of tinnitus. 28 Moreover, glutamate is involved in GABA signaling and the disturbances of the signaling may occur in tinnitus. For instance, tinnitus was associated with a reduction in auditory cortex GABA concentration. 29 As indicated by an animal study, decreased GABAergic inhibition might be a possible mechanism for subjective tinnitus. 30 Furthermore, a reduction in the level of the GABAB receptor subunits in the rat inferior colliculus might be relevant for the generation of a tinnitus-like behavior. 31 Besides, several studies have reported that tinnitus was attributed to abnormal changes in both glutamate and GABA. For example, chronic tinnitus might involve downregulation of inhibitory neurotransmission mediated by GABA and/or upregulation of excitatory neurotransmission mediated by glutamate. These bidirectional and region-specific alterations in GABA and glutamate might reflect large-scale changes in inhibitory and excitatory equilibria accompanying chronic tinnitus. KDP in this study was consistent with findings of earlier reports, which described partially abnormal metabolic characteristics in tinnitus. Serotonin or 5-hydroxytryptamine (5-HT) is principally released from the neurons of the raphe nuclei in the brain. It has been reported that the excitability of local 5-HTergic neural circuits in the dorsal raphe nucleus was elevated in tinnitus, which might contribute to the elevated serotonin level in the brain. 33 It has been also revealed that serotonin exerted a potent influence on fusiform cells by altering their intrinsic properties, which might enhance the sensitivity of the DCN to sensory input . 34 The DCN is the site of the first synapses formed by auditory cochlear nerve fibers within the central auditory pathway, where the basic computations underlying sound localization are initiated. Therefore, heightened activity in the DCN might underlie central tinnitus. 34 Besides, it has been proposed that activation of serotonergic neurons likely influenced a number of auditory and non-auditory regions known to be involved in tinnitus. 35 Serotonergic input played a specific role in auditory information processing, which suggested that disturbances of this input might contribute to tinnitus. 36 Apart from serotonin, it was confirmed that the concentration of 5-hydroxyindoleacetic acid (5-HIAA), a metabolite of serotonin, was significantly correlated with the duration of tinnitus. 37 Therefore, deregulation of serotonin signaling was likely to be an important phenomenon in tinnitus, so serotonin levels in tinnitus patients might have diagnostic and clinical value. 37 This study showed that both glutamate and serotonin were also involved with calcium signaling. Several calcium-signaling genes were known to be differentially expressed in age-or noise-induced hearing impairment-tinnitus and hearing loss. 38 Thus, alteration of calcium signaling, as indicated by upregulation of glutamate and serotonin, might be partially responsible for ST/KDP pathogenesis. This study also identified taurine as a tinnitus biomarker. In mammals, taurine is synthesized in the pancreas. It crossed the blood-brain barrier and played an essential role in central nervous system. 39 Taurine was implicated in a wide array of physiological phenomena, including inhibitory neurotransmission, calcium homeostasis, and protection against glutamate excitotoxicity. 40 Taurine, which acts as a membrane stabilizer, was found at a lower concentration in virtually all cochlear regions during tinnitus, and, therefore, was likely to be involved in tinnitus pathogenesis. 41 Data from our present study confirmed the results of those earlier reports. Orotic acid was produced in the body by a cytoplasmic enzyme of the pyrimidine biosynthesis pathway. 42 Both orotic acid and glutamate are involved in pyrimidine biosynthesis. Sound transduction and auditory neurotransmission in the cochlea were influenced by extracellular purines and pyrimidines. 43 So it was concluded that upregulated orotic acid level in ST/KDP observed in this study could also be a biomarker associated with tinnitus. 8-oxoguanine was degraded into urate by 8-oxoguanine amino hydrolase in the body, and the level of urate, one of the purine metabolism molecules, was known to be disturbed during hearing loss. 44 Therefore, upregulated 8-oxoguanine concentration might also be a distinct metabolic characteristic of ST/KDP. In conclusion, the metabolic pathogenesis in ST/KDP subjects was characterized by alterations of five metabolic biomarkers such as upregulated glutamate, serotonin, orotic acid and 8-oxoguanine, as well as downregulated taurine, additionally, perturbations of particular biological pathways including calcium signaling, GABA receptor signaling, purine and pyrimidine biosynthesis, taurine biosynthesis and serotonin receptor signaling.
